Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes
Phase of Trial: Phase II/III
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Quetiapine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 09 Aug 2016 Status changed from active, no longer recruiting to completed.
- 09 Jul 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 22 Jan 2014 Planned number of patients changed from 600 to 340 as reported by ClinicalTrials.gov record.